BREATHING LIFE INTO THE TREATMENT OF RESPIRATORY AILMENTS
Our lung and respiratory clinical trial capabilities cover Phase I, II III, IV, RWE and reimbursement strategies
With rapid growth in the inhaled medicine market, Fortrea’s expertise offers a competitive edge
The combination of our industry experts and capabilities enables us to help you get your treatment to market quickly and effectively
Fortrea provides access to an extensive inhalation team and facility, medical device development and strategies for clinical trials and post-market reimbursement for organizations pursuing a treatment compound or device for respiratory and lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), lung cancers, cystic fibrosis (CF) or idiopathic pulmonary fibrosis.
As a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling services, Fortrea partners with emerging and large biopharma and medical device and diagnostic companies to drive healthcare innovation throughout the world.
